Posted by Michael Wonder on 31 May 2018
Pfizer's Xalkori makes it onto Cancer Drugs Fund
31 May 2018 - NICE has published draft guidance recommending that Pfizer's Xalkori (crizotinib) to treat ROS1-positive advanced non-small-cell lung cancer is made available via the Cancer Drugs Fund.
ROS1-positive lung cancer is a recently discovered subtype of the disease, and NICE said that the evidence for Xalkori's effectiveness in treating it is limited.
In January, the appraisal committee concluded that Xalkori appears to be a promising treatment but limited data meant the cost-effectiveness estimates are highly uncertain.
